文摘
摘要目的:评估是否脉络丛(CP)扩大发生在系统性红斑狼疮(SLE)患者与健康对照组相比(HC)和与auto-antibody状态有关,神经介入(NP-SLE)和结构脑损伤。
背景:CP扩大被建议作为一种多发性硬化症、神经炎症状态的标志与疾病活动和临床残疾。CP参与系统性红斑狼疮免疫病理最近假设,然而,CP扩大之间的关联,auto-antibody地位,临床表现和大脑结构损伤尚未充分探讨。
设计/方法:大脑3 t dual-echo和3 d t1序列从32获得系统性红斑狼疮患者和32岁,sex-matched HC。CP成交量手动从3 d t1加权获得扫描和规范化的头部大小。CP卷比较HC与系统性红斑狼疮患者根据auto-antibody分层状态(anti-antiphospholipid (APA)和anti-double-stranded DNA (ADNA)抗体)和NP参与使用线性模型。CP体积之间的关联和临床MRI和结构变量使用线性回归分析进行了探讨。
结果:HC相比,只有系统性红斑狼疮患者积极的自体抗体状态(APA (n = 18)或ADNA (n = 24)显示明显高于白质(WM)病变体积(LV) (p = 0.020和0.033),而只有系统性红斑狼疮患者APA抗体有显著CP扩大(p = 0.013)。HC相比,non-NP-SLE (n = 20)和NP-SLE病人(n = 12)显示明显高于CP卷(p = 0.002和< 0.001),而WM LV明显高于只在NP-SLE (p = 0.001)。non-NP-SLE相比,NPSLE患者明显高于CP卷(p = 0.024)和WM LV (p = 0.015)。没有群体间的大脑体积差异被发现。无显著关联的CP体积与疾病持续时间和活动,WM LV和规范化的脑容量被发现。
结论:CP扩张发生在系统性红斑狼疮患者,尤其是在那些APA和NP参与,表明其潜在作用的病理生理学系统性红斑狼疮相关的大脑的参与。
披露:Gueye博士没有披露。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在百时美施贵宝公司的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在赛诺菲Genzyme的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在诺华的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在罗氏的演讲人。Preziosa先生已经收到个人薪酬在500 - 4999美元的范围在默克的演讲人。朱塞佩·a·拉米雷斯没有披露。艾瑞卡Bozzolo没有披露。瓦伦蒂娜Canti没有披露。莫妮卡Margoni接到MAGNIMS研究支持。 Alessandro Meani has nothing to disclose. Patrizia Rovere-Querini has nothing to disclose. Angelo Manfredi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Clinical & Experimental Immunology. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva. The institution of Maria Assunta Rocca has received research support from Italian Ministry of Health, MS Society of Canada and Fondazione Italiana Sclerosi Multipla. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
